The global embolic protection devices market size is expected to grow at a CAGR of 8% to reach USD 688 million by 2025. The market is growing mainly due to the rising cardiovascular and neurovascular diseases across the globe. Globally, such diseases are primarily caused by several factors, including obesity, lack of physical activities, and hypertension. Epidemiological studies have reported that cardiac and neuro diseases are recognized as the leading cause of morbidity and mortality worldwide. Several factors influence the growth of the global embolic protection devices market. The rising demand for cerebral embolic protection devices is expected to drive the growth of the market. Growing demand for cerebral protection while performing neurovascular surgeries such as carotid artery stenting is another driving factor for the global embolic protection devices market.
- The hospital end-user segment is expected to achieve an incremental growth of over $100 million by 2025. The growth is due to the high uptake of EPDs in several private and public hospitals across the globe.
- North America is expected to witness the highest growth rate during the forecast period. The growth is on account of a large patient pool, technological advancements, and better product availability.
- The increasing preference for minimally-invasive surgeries is one of the key driving factors of the market.
GLOBAL EMBOLIC PROTECTION DEVICES MARKET SEGMENTATION
This research report includes a detailed segmentation by
INSIGHTS BY PRODUCT
The filter devices segment accounts for the maximum market share. This is due to effective clinical results for percutaneous and transcatheter surgical techniques to treat cardiac and neuro disorders. It is expected to grow at the highest CAGR owing to greater safety and procedural outcomes. The high success rate and the growing patient pool for several cardiac and neuro diseases is likely to influence segment growth. The filter devices have a larger profile than the occlusion devices segment. Availability of latest-generation devices Such as ANGIOGUARD RX Guidewire System, by Cardinal Health & FilterWire EZ by Boston Scientific, is driving the growth of the filter devices segment.
The occlusion devices segment is expected to reach over $100 million by 2025. Improved procedural outcomes for several occlusion devices, which aim to reduce or eliminate distal embolization during percutaneous coronary and carotid interventions, have increased the adoption of occlusion devices.
INSIGHTS BY APPLICATION
The cardiac & peripheral segment is expected to retain its market dominance during the forecast period. Filter or occlusion embolic protection devices have proven clinical benefits and can be used when technically feasible for cardiac & peripheral applications. As a result, there is a huge demand for EPDs for treating CVDs across the globe. While APAC is expected to grow at the highest CAGR, North America is likely to retain dominance in the market.
The demand for several embolic protection devices (EPD) is growing steadily for neuro applications such as Carotid Artery Stenting (CAS). Several major and emerging vendors are offering innovative EPDs to reduce the risk of stroke due to embolic events. Moreover, the availability of integrated and advanced embolic protection devices is likely to drive the growth of the neuro application segment.
INSIGHTS BY INDICATION
Despite potential growth opportunities of EPDs to treat saphenous vein graft (SVG), the recent eruption of the COVID-19 pandemic is causing unprecedented challenges to perform PCI procedures. The spread of the virus has disrupted daily lives with educational and commercial institutions shutting down across cities or countries and travel and large gatherings prohibited.
EPDs have become a standard for anatomically suitable patients undergoing SVG PCI. Therefore, many players have been focusing on the development of clinically advanced EPD for SVG disease over the years. This is increasing the global embolic protection devices market size.
Carotid artery stenting (CAS) is considered as the preferred treatment for patients with symptomatic carotid stenosis. The use of embolic protection devices is feasible and safe for patients with a low incidence of neurology complications. Therefore, several vendors are strategizing to develop and commercialize embolic protection devices for carotid interventions.
INSIGHTS BY END-USER
Healthcare professionals in hospitals use advanced embolic protection stents for cardiac & peripheral and neuro procedures. The market is growing at a healthy rate primarily due to the higher adoption of latest generation EPDs, as a majority of patients prefer to visit hospitals. The aging population and the increasing pool of patient populations with CVDs and neuro disease are the major factors driving the market growth of the hospital segment.
Specialty cardiac centers have a high number of highly skilled cardiac surgeons. They perform modern procedures such as PCI, Transcatheter aortic valve replacement with the embolic protection system. In these centers, a patient can obtain services ranging from diagnosis, treatment, and effective post-surgery follow-up due to the availability of superior infrastructure compared to hospitals. This can be attributed to the highest growth rate of the specialty cardiac center segment.
The ability of ambulatory surgical centers to safely perform complex procedures by following backup protocols is expected to witness steady demand. The demand is growing in developed countries as the end-users are shifting from open surgeries to MI-based surgical techniques. The growth in technological advancements, less invasive surgeries, and outpatient services are contributing to the market growth of ASCs.
INSIGHTS BY GEOGRAPHY
North America is the single largest market for embolic protection companies. The region has become strategically important for several prominent vendors, such as Boston Scientific and Abbott. Medtronic embolic protection devices are expected to be innovative as the company is investing significant expenditure in R&D. The US is the major revenue contributor to the market, accounted for a share of 90% in 2019.
Europe is the second-largest market for embolic protection devices and accounted for a share of 34% in 2019. It is growing at a healthy rate and is expected to grow at a similar pace during the forecast period. Germany, France, the UK, Spain, and Italy are the major revenue contributors to this region.
The APAC region was estimated to have 57% of the global elderly population in 2017. The percentage is projected to increase to 61% by 2050. Such a rapidly growing aging population will have a higher risk of having various cardiac disorders. The aging population will increase the demand for these devices during the forecast period.
INSIGHTS BY VENDORS
The global embolic protection devices market share is highly concentrated. The market has the presence of few established players holding the majority of the market share. Vendors are offering several filter and occlusion embolic protection devices. They are competing based on factors such as technology advances, safety features, regulatory approvals, marketing strategies, and distribution channels.
Boston Scientific, Abbott Laboratories, and Medtronic are the key vendors in the global market. These companies have a wide geographic footprint, diversified product portfolio, and a strong focus on product innovations and R&D. Medtronic’s spiderfx device offers optimal vessel sizing.
The global embolic protection devices market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:
- Cardiovascular & Peripheral
- Carotid Artery Diseases
- Aortic Stenosis
- Peripheral Artery Disease
- Acute Myocardial Infraction
- Specialty Cardiac Centers
- Freestanding CATH Labs
- North America
- South Korea
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia